|
21 Companies |
|
19 Products |
|
19 Products |
|
23 Mechanisms of Action |
|
0 Trials |
|
101 News |
|
| 123» |
- || bertilimumab (iCo-008) / iCo Therap, AstraZeneca
Trial completion, Trial completion date: Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid (clinicaltrials.gov) - Jun 1, 2018
P2, N=11, Completed, Sponsor: Immune Pharmaceuticals
Recruiting --> Completed | Trial completion date: Jul 2018 --> Apr 2018
- | Trial completion, Trial completion date: Study of Enzyme Supplements to Treat Celiac Disease (clinicaltrials.gov) - Mar 6, 2018
P1/2, N=38, Completed, Sponsor: Heim Pal Children's Hospital
Recruiting --> Completed | Trial completion date: Jul 2018 --> Apr 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2015 --> Dec 2017
- bertilimumab (iCo-008) / iCo Therap, AstraZeneca
Enrollment change, Trial primary completion date: Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid (clinicaltrials.gov) - Jan 5, 2018
P2, N=10, Recruiting, Sponsor: Immune Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Dec 2015 --> Dec 2017 N=15 --> 10 | Trial primary completion date: Mar 2017 --> Apr 2018
- | dapsone / Generic mfg.
Phase classification, Trial termination, Trial primary completion date: Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis (clinicaltrials.gov) - Dec 14, 2017
P4, N=1, Terminated, Sponsor: Vanderbilt University Medical Center
N=15 --> 10 | Trial primary completion date: Mar 2017 --> Apr 2018 Phase classification: P=N/A --> P4 | Not yet recruiting --> Terminated | Trial primary completion date: Apr 2011 --> Mar 2012; poor enrollment and lack of funding
- | Phase classification: Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - Jun 23, 2017
P2, N=7, Completed, Sponsor: Vanderbilt University Medical Center
Phase classification: P=N/A --> P4 | Not yet recruiting --> Terminated | Trial primary completion date: Apr 2011 --> Mar 2012; poor enrollment and lack of funding Phase classification: P=N/A --> P2
- | Rituxan (rituximab) / Roche
Trial completion: Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus (clinicaltrials.gov) - Jun 14, 2017
P3, N=90, Completed, Sponsor: University Hospital, Rouen
Phase classification: P=N/A --> P2 Active, not recruiting --> Completed
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial withdrawal: Topical Infliximab in Autoimmune Eyes With Keratoprosthesis (clinicaltrials.gov) - Apr 7, 2017
P1/2, N=0, Withdrawn, Sponsor: James Chodosh, MD, MPH
Active, not recruiting --> Completed Enrolling by invitation --> Withdrawn
- | Nucala (mepolizumab) / GSK
Trial completion: Anti-IL-5 Therapy in Bullous Pemphigoid (BP) (clinicaltrials.gov) - Feb 28, 2017
P2, N=32, Completed, Sponsor: University Hospital Inselspital, Berne
Enrolling by invitation --> Withdrawn Active, not recruiting --> Completed
- Nucala (mepolizumab) / GSK
Enrollment closed: Anti-IL-5 Therapy in Bullous Pemphigoid (BP) (clinicaltrials.gov) - Feb 7, 2017
P2, N=32, Active, not recruiting, Sponsor: University Hospital Inselspital, Berne
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment change, Trial withdrawal, Trial primary completion date: DIVERT: Diversion of Flow in Intracranial VErtebral and Blood Blister-like Ruptured Aneurysms Trial: A Randomized Trial Comparing Pipeline Flow Diversion and Best-Standard-Treatment (clinicaltrials.gov) - Nov 22, 2016
P=N/A, N=0, Withdrawn, Sponsor: Centre hospitalier de l'Universit
Recruiting --> Active, not recruiting N=420 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Jan 2021 --> Oct 2016
- | bertilimumab (iCo-008) / iCo Therap, AstraZeneca
Trial initiation date: Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid (clinicaltrials.gov) - Nov 9, 2016
P2, N=15, Recruiting, Sponsor: Immune Pharmaceuticals
N=420 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Jan 2021 --> Oct 2016 Initiation date: Jul 2015 --> Feb 2016
- bertilimumab (iCo-008) / iCo Therap, AstraZeneca
Trial primary completion date: Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid (clinicaltrials.gov) - Oct 21, 2016
P2, N=15, Recruiting, Sponsor: Immune Pharmaceuticals
Initiation date: Jul 2015 --> Feb 2016 Trial primary completion date: Dec 2016 --> Mar 2017
- Kepivance (palifermin) / SOBI, Amgen
Trial termination: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis (clinicaltrials.gov) - Aug 12, 2016
P1/2, N=1, Terminated, Sponsor: Brett King
Trial primary completion date: Dec 2016 --> Mar 2017 Recruiting --> Terminated; Low enrollment numbers precluded completion of the study during a reasonable amount of time.
- Trial completion: Salivary Gland Transplantation in the Treatment of Dry Eye in Patients With Stevens-Johnson Syndrome. (clinicaltrials.gov) - Aug 12, 2016
P=N/A, N=19, Completed, Sponsor: Federal University of São Paulo
Recruiting --> Terminated; Low enrollment numbers precluded completion of the study during a reasonable amount of time. Enrolling by invitation --> Completed
- cyclophosphamide / Generic mfg.
Enrollment change: Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus (clinicaltrials.gov) - Feb 18, 2016
P2, N=9, Terminated, Sponsor: New York University School of Medicine
Enrolling by invitation --> Completed N=24 --> 9
- bertilimumab (iCo-008) / iCo Therap, AstraZeneca
Trial primary completion date: Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid (clinicaltrials.gov) - Feb 16, 2016
P2, N=15, Recruiting, Sponsor: Immune Pharmaceuticals
N=24 --> 9 Trial primary completion date: Feb 2016 --> Dec 2016
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial withdrawal, Trial primary completion date: Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) (clinicaltrials.gov) - Nov 10, 2015
P1/2, N=0, Withdrawn, Sponsor: Massachusetts Eye and Ear Infirmary
Trial primary completion date: Feb 2016 --> Dec 2016 Recruiting --> Withdrawn | Trial primary completion date: Jul 2015 --> Jan 2015
- Trial primary completion date, IO biomarker: Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid (clinicaltrials.gov) - Nov 10, 2015
P=N/A, N=130, Recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
Recruiting --> Withdrawn | Trial primary completion date: Jul 2015 --> Jan 2015 Trial primary completion date: Nov 2015 --> Nov 2016
- ligelizumab (QGE 031) / Novartis
Trial termination: Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment (clinicaltrials.gov) - Oct 23, 2015
P2, N=20, Terminated, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2015 --> Nov 2016 Completed --> Terminated; This study was stopped after Part 1 completed and was terminated because the predefined criteria of efficacy was not reached ( >50% better then placebo)
- | Trial completion: A Study to Evaluate Use of Induced Skin Blisters in Adult Participants With Atopic Dermatitis, Allergic Asthma and Atopic Healthy Participants (clinicaltrials.gov) - Oct 6, 2015
P0, N=46, Completed, Sponsor: Janssen Research & Development, LLC
Completed --> Terminated; This study was stopped after Part 1 completed and was terminated because the predefined criteria of efficacy was not reached ( >50% better then placebo) Recruiting --> Completed
- Trial withdrawal: Pilot Study Evaluating the Efficiency and the Tolerance of the PDT in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary DEB (clinicaltrials.gov) - Oct 1, 2015
P=N/A, N=0, Withdrawn, Sponsor: Centre Hospitalier Universitaire de Nice
Recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment closed, Trial primary completion date: Study of Enzyme Supplements to Treat Celiac Disease (clinicaltrials.gov) - Aug 19, 2015
P1/2, N=40, Active, not recruiting, Sponsor: Heim Pal Children's Hospital
Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2009 --> Dec 2014
- | bertilimumab (iCo-008) / iCo Therap, AstraZeneca
Enrollment open: Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid (clinicaltrials.gov) - Aug 5, 2015
P2, N=15, Recruiting, Sponsor: Immune Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2009 --> Dec 2014 Not yet recruiting --> Recruiting
- | ligelizumab (QGE 031) / Novartis
Trial completion, Enrollment change: Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment (clinicaltrials.gov) - Apr 15, 2015
P2, N=20, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed | N=42 --> 20
- | bertilimumab (iCo-008) / iCo Therap, AstraZeneca
Trial initiation date, Trial primary completion date: Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid (clinicaltrials.gov) - Apr 15, 2015
P2, N=15, Not yet recruiting, Sponsor: Immune Pharmaceuticals
Recruiting --> Completed | N=42 --> 20 Initiation date: Aug 2014 --> Jun 2015 | Trial primary completion date: Feb 2015 --> Feb 2016
- Enrollment change, Trial termination: Multidrug Blister Pack Study (clinicaltrials.gov) - Apr 15, 2015
P=N/A, N=11, Terminated, Sponsor: Kurt Hersberger
Initiation date: Aug 2014 --> Jun 2015 | Trial primary completion date: Feb 2015 --> Feb 2016 N=200 --> 11 | Suspended --> Terminated; Difficulties with patient recruitement
- Trial completion, Enrollment change, Trial primary completion date: Visual Distraction as a Means of Enhancing Child Resistance (clinicaltrials.gov) - Apr 7, 2015
P=N/A, N=229, Completed, Sponsor: Michigan State University
N=200 --> 11 | Suspended --> Terminated; Difficulties with patient recruitement Recruiting --> Completed | N=500 --> 229 | Trial primary completion date: Dec 2014 --> Apr 2015
- Enrollment open: A Study to Evaluate Use of Induced Skin Blisters in Adult Participants With Atopic Dermatitis, Allergic Asthma and Atopic Healthy Participants (clinicaltrials.gov) - Mar 17, 2015
P0, N=44, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed | N=500 --> 229 | Trial primary completion date: Dec 2014 --> Apr 2015 Not yet recruiting --> Recruiting
- Enrollment change, Trial termination: A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa (clinicaltrials.gov) - Mar 10, 2015
P4, N=3, Terminated, Sponsor: University Hospital, Basel, Switzerland
Not yet recruiting --> Recruiting N=18 --> 3 | Recruiting --> Terminated
- Clinical: A Study to Evaluate Use of Induced Skin Blisters in Adult Participants With Atopic Dermatitis, Allergic Asthma and Atopic Healthy Participants (clinicaltrials.gov) - Jan 22, 2015
P0, N=44, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ligelizumab (QGE 031) / Novartis
Trial primary completion date: Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment (clinicaltrials.gov) - Jan 20, 2015
P2, N=42, Recruiting, Sponsor: Novartis Pharmaceuticals
N=18 --> 3 | Recruiting --> Terminated Trial primary completion date: Nov 2015 --> Mar 2015
- Trial completion, Enrollment change, Trial primary completion date: Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=7, Completed, Sponsor: Vanderbilt University
Trial primary completion date: Nov 2015 --> Mar 2015 Recruiting --> Completed | N=20 --> 7 | Trial primary completion date: Mar 2014 --> Oct 2014
- Tyrisa (darapladib) / GSK
Trial completion, Enrollment change, IO biomarker: Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Nov 17, 2014
P1, N=9, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed | N=20 --> 7 | Trial primary completion date: Mar 2014 --> Oct 2014 Recruiting --> Completed | N=16 --> 9
- Nucala (mepolizumab) / GSK
Trial primary completion date: Anti-IL-5 Therapy in Bullous Pemphigoid (BP) (clinicaltrials.gov) - Nov 14, 2014
P2, N=30, Recruiting, Sponsor: University Hospital Inselspital, Berne
Recruiting --> Completed | N=16 --> 9 Trial primary completion date: Oct 2014 --> Dec 2016
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment open: Topical Infliximab in Autoimmune Eyes With Keratoprosthesis (clinicaltrials.gov) - Nov 4, 2014
P1/2, N=4, Enrolling by invitation, Sponsor: James Chodosh, MD, MPH
Trial primary completion date: Oct 2014 --> Dec 2016 Not yet recruiting --> Enrolling by invitation
- Trial primary completion date: A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa (clinicaltrials.gov) - Nov 3, 2014
P4, N=18, Recruiting, Sponsor: University Hospital, Basel, Switzerland
Not yet recruiting --> Enrolling by invitation Trial primary completion date: Jun 2014 --> Dec 2014
- Enrollment closed: DIVERT: Diversion of Flow in Intracranial VErtebral and Blood Blister-like Ruptured Aneurysms Trial: A Randomized Trial Comparing Pipeline Flow Diversion and Best-Standard-Treatment (clinicaltrials.gov) - Oct 15, 2014
P=N/A, N=420, Active, not recruiting, Sponsor: Centre hospitalier de l'Universit
Trial primary completion date: Jun 2014 --> Dec 2014 Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Trial primary completion date: Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid (clinicaltrials.gov) - Sep 8, 2014
P3, N=18, Completed, Sponsor: University Hospital, Rouen
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Dec 2012 --> Dec 2013
- | Rituxan (rituximab) / Roche
Enrollment closed: Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus (clinicaltrials.gov) - Sep 8, 2014
P3, N=90, Active, not recruiting, Sponsor: University Hospital, Rouen
Recruiting --> Completed | Trial primary completion date: Dec 2012 --> Dec 2013 Recruiting --> Active, not recruiting
- | bertilimumab (iCo-008) / iCo Therap, AstraZeneca
New P2 trial: Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid (clinicaltrials.gov) - Aug 27, 2014
P2, N=15, Not yet recruiting, Sponsor: Immune Pharmaceuticals
- Trial completion: Study of Inflammatory Mechanisms in Epidermolysis Bullosa Simplex- Dowling Meara (clinicaltrials.gov) - Jul 30, 2014
P=N/A, N=6, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
Recruiting --> Active, not recruiting Recruiting --> Completed
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial primary completion date: Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. (clinicaltrials.gov) - Jul 2, 2014
P3, N=10, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Recruiting --> Completed Trial primary completion date: Jan 2014 --> Jun 2014
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial completion, Trial primary completion date: Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. (clinicaltrials.gov) - Jul 2, 2014
P3, N=10, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Trial primary completion date: Jan 2014 --> Jun 2014 Recruiting --> Completed | Trial primary completion date: Jan 2014 --> Jun 2014
- ligelizumab (QGE 031) / Novartis
Trial primary completion date: Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment (clinicaltrials.gov) - May 20, 2014
P2, N=42, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Jan 2014 --> Jun 2014 Trial primary completion date: Aug 2015 --> Nov 2015
- ligelizumab (QGE 031) / Novartis
Trial completion date: Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment (clinicaltrials.gov) - May 20, 2014
P2, N=42, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2015 --> Nov 2015 Trial completion date: Aug 2015 --> Nov 2015
- Trial primary completion date: Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 14, 2014
P=N/A, N=13, Completed, Sponsor: Stanford University
Trial completion date: Aug 2015 --> Nov 2015 Trial primary completion date: Jan 2015 --> May 2014
- Trial completion date: Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 14, 2014
P=N/A, N=13, Completed, Sponsor: Stanford University
Trial primary completion date: Jan 2015 --> May 2014 Trial completion date: Jan 2015 --> May 2014
- Trial completion: Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 14, 2014
P=N/A, N=13, Completed, Sponsor: Stanford University
Trial completion date: Jan 2015 --> May 2014 Recruiting --> Completed
- Trial primary completion date: Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate) (clinicaltrials.gov) - May 5, 2014
P2, N=18, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
Recruiting --> Completed Trial primary completion date: May 2012 --> Jul 2013
- Trial completion date: Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate) (clinicaltrials.gov) - May 5, 2014
P2, N=18, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
Trial primary completion date: May 2012 --> Jul 2013 Trial completion date: May 2012 --> Jul 2013